836,397 Shares in BioMarin Pharmaceutical Inc. $BMRN Purchased by Fuller & Thaler Asset Management Inc.

Key Points

• Fuller & Thaler Asset Management Inc. acquired 836,397 shares of BioMarin Pharmaceutical Inc., valued at approximately $59.1 million, during the first quarter.
• Several institutional investors, including Nuveen LLC and Northern Trust Corp, have also increased their holdings in BioMarin, with institutional investors now owning 98.71% of the stock.
• Analyst ratings for BioMarin are generally positive, with an average rating of "Moderate Buy" and a target price around $93.17.

Fuller & Thaler Asset Management Inc. acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 836,397 shares of the biotechnology company's stock, valued at approximately $59,125,000. Fuller & Thaler Asset Management Inc. owned 0.44% of BioMarin Pharmaceutical as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Nuveen LLC acquired a new position in shares of BioMarin Pharmaceutical during the 1st quarter worth about $184,475,000. Northern Trust Corp grew its position in shares of BioMarin Pharmaceutical by 16.2% during the 4th quarter. Northern Trust Corp now owns 1,725,039 shares of the biotechnology company's stock worth $113,387,000 after buying an additional 240,681 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of BioMarin Pharmaceutical by 7.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company's stock worth $108,319,000 after buying an additional 108,806 shares during the period. AQR Capital Management LLC grew its position in shares of BioMarin Pharmaceutical by 114.5% during the 4th quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company's stock worth $84,371,000 after buying an additional 685,099 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of BioMarin Pharmaceutical by 19.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company's stock worth $69,351,000 after buying an additional 174,634 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wedbush restated an "outperform" rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. The Goldman Sachs Group decreased their target price on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating for the company in a research report on Monday, May 5th. Wolfe Research set a $95.00 price objective on BioMarin Pharmaceutical and gave the company an "outperform" rating in a report on Tuesday, July 15th. Wall Street Zen upgraded BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Citigroup cut their price objective on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $93.17.

BioMarin Pharmaceutical Stock Down 0.2%

BMRN stock opened at $57.44 on Tuesday. BioMarin Pharmaceutical Inc. has a twelve month low of $52.93 and a twelve month high of $94.85. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The stock's 50 day moving average is $57.42 and its 200-day moving average is $61.50. The firm has a market capitalization of $11.03 billion, a PE ratio of 17.04, a P/E/G ratio of 0.74 and a beta of 0.18.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.